Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Intravenous Doses of FR104 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2016
At a glance
- Drugs FR 104 (Primary)
- Indications Rheumatoid arthritis; Transplant rejection
- Focus Adverse reactions; First in man
- Sponsors OSE Immunotherapeutics
- 17 Nov 2016 According to OSE Immunotherapeutics media release, positive results were published in the Journal of Immunology.
- 20 Jul 2016 Status changed from recruiting to completed.
- 01 Mar 2016 New trial record